BAX vs ICUI: How Baxter International and ICU Medical Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BAX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and ICUI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and ICUI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

ICU Medical makes the plumbing of hospital drug delivery. Its Consumables segment sells IV sets, needle-free connectors (the CLAVE family it has built its reputation on), oncology and vascular access products, and tracheostomy devices. Infusion Systems sells the large volume, syringe and ambulatory pumps that push those fluids, including the Plum Duo and Plum Solo platforms plus the LifeShield safety software layer and the CADD and Medfusion pumps inherited from Smiths Medical. Vital Care is the catch-all for temperature management, respiratory, cardiac monitoring and the IV solutions business, most of which now sits inside Otsuka ICU Medical LLC, the joint venture formed in May 2025 when ICU sold 60% of IV Solutions to Otsuka Pharmaceutical Factory America and kept a 40% stake. Revenue for full year 2025 was about $2.23 billion, down roughly 6% on a reported basis almost entirely because of that deconsolidation, with Consumables at about $1.11 billion, Infusion Systems at about $684 million and Vital Care at about $438 million.

Full ICUI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• ICUI drivers: The Infusion Systems replacement cycle; Gross margin recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For ICUI, regulatory and quality exposure is the most specific risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAX if you believe its drivers more; ICUI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and ICUI guides.

BAX. Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

ICUI. At roughly $187 per share, ICUI trades near 21 times the midpoint of its guided adjusted EPS and around 13 times enterprise value to guided adjusted EBITDA, which is a discount to large-cap medical device peers and reflects the leverage plus the unfinished integration. The gap between GAAP and adjusted numbers is unusually wide here, with FY2026 GAAP EPS guided to roughly $1.03 to $1.74 originally and raised to roughly $2.89 to $3.29, because acquisition amortization, restructuring and integration costs are excluded from the adjusted figures. ICU Medical pays no dividend and directs its cash toward debt repayment instead.

Headline figures (approximate, July 2026): BAX shows revenue (ttm, continuing ops) ~$10.7B, q1 2026 sales ~$2.7B, q1 2026 adjusted eps ~$0.36, market cap ~$11.5B; ICUI shows revenue (fy2025) ~$2.23 billion, q2 2026 revenue ~$552 million, ~6% organic growth, adjusted ebitda (fy2026 guide) ~$415 million to ~$435 million, adjusted eps (fy2026 guide) ~$8.60 to ~$9.00.

BAX and ICUI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and ICUI exposure against your real portfolio. It is not an investment adviser.